Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer

Journal of Urology

Volumn 169, Issue 2, 2003, Pages 445-457

  Karazanashvili, Guram ^a,b   Abrahamsson, Per Anders ^a,b  

^a TBILISI STATE MEDICAL UNIVERSITY   (Georgia)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Kallikreins; Prostate; Prostate specific antigen; Prostatic neoplasms; Prostatitis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN;

BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOASSAY; MALE; MALE GENITAL TRACT CANCER; ORGAN SIZE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; RECTUM; REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0037305887     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)63932-8     Document Type: Review

References (135)

1. WHO: The World Health Report. http.//www.who.org/whr, 1999
2. WHO: World Health Report. http://www.who.org/whr, 2000
3. Brawer, M. K.: Screening for prostate cancer. Semin Surg Oncol, 18: 29, 2000
4. Denis, L., Mettlin, C., Carter, H. B., De Konnig, H. J., Fourcade, R., Fournier, G. et al: Early Detection and screening. In: Proceedings of the 2nd International Consultation on Prostate Cancer. Edited by G. Murphy, S. Khoury, A. Partin and L. Denis. Paris, France: Health Publication Ltd., June 27-29, 1999
5. Abrahamsson, P. A., Lilja, H. and Oesterling, J. E.: Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am, 24: 353, 1997
6. Schroder, F. H.: Screening, early detection, and treatment of prostate cancer: a European view. Urology, suppl., 46: 62, 1995
7. Lilja, H.: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest, 76: 1899, 1985
8. Christensson, A., Laurell, C. B. and Lilja, H.: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem, 194: 755, 1990
9. Ahlgren, G., Rannevik, G. and Lilja, H.: Impaired secretory function of the prostate in men with oligoasthenozoospermia. J Androl, 16: 491, 1995
10. Lilja, H. and Abrahamsson, P. A.: Three predominant proteins secreted by the human prostate gland. Prostate, 12: 29, 1988
11. Lilja, H., Christensson, A., Dahlen, U., Matikainen, M. T., Nilsson, O., Pettersson, K. et al: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem, 37: 1618, 1991
12. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K. and Alfthan, O.: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res, 51: 222, 1991
13. Christensson, A., Bjork, T., Nilsson, O., Dahlen, U., Matikainen, M. T., Cockett, A. T. et al: Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol, 150: 100, 1993
14. Oesterling, J. E., Jacobsen, S. J., Klee, G. G., Pettersson, K., Piironen, T., Abrahamsson, P. A. et al: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol, 154: 1090, 1995
15. Stenman, U. H., Leinonen, J. and Zhang, W. M.: Problems in the determination of prostate specific antigen. Eur J Clin Chem Clin Biochem, 34: 735, 1996
16. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 317: 909, 1987
17. Stenman, U. H.: Prostate-specific antigen, clinical use and staging: an overview. Br J Urol, suppl., 79: 53, 1997
18. Christensson, A. and Lilja, H.: Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem, 220: 45, 1994
19. Papsidero, L. D., Wang, M. C., Valenzuela, L. A., Murphy, G. P. and Chu, T. M.: A prostate antigen in sera of prostate cancer patients. Cancer Res, 40: 2428, 1980
20. Kuriyama, M., Wang, M. C., Lee, C.-I., Papsidero, L. D., Lillian, C. S., Inaji, H. et al: Use of human prostate-specific antigen in monitoring of prostate cancer. Cancer Res, 41: 3874, 1981
21. Coley, C. M., Barry, M. J., Fleming, C., Wasson, J. H., Fahs, M. C. and Oesterling, J. E.: Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: early detection strategies. Urology, 46: 125, 1995
22. Brawer, M. K., Benson, M. C., Djavan, B., Lilja, H., Semjonow, A., Su, S. et al: Prostate serum markers. In: Proceedings of the 2nd International Consultation on Prostate Cancer. Edited by G. Murphy, S. Khoury, A. Partin and L. Denis. Paris, France: Health Publication Ltd., June 27-29, 1999
23. Powell, C. S., Fielding, A. M., Rosser, K., Ames, A. C. and Vaughton, K. C.: Prostate specific antigen - a screening test for prostatic cancer? Br J Urol, 64: 504, 1989
24. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. et al: Measurement of prostatespecific antigen in serum as a screening test for prostate cancer. N Engl J Med, 324: 1156, 1991
25. Babaian, R. J. and Camps, J. L.: The role of prostate-specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy. Cancer, 68: 2060, 1991
26. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.-I. et al: Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol, part 2, 147: 846, 1992
27. Cooner, W. H., Mosley, B. R., Rutherford, C. L., Beard, J. H., Pond, H. S., Terry W. J. et al: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol, 143: 1146, 1990
28. Crawford, E. D., Leewansangtong, S., Goktas, S., Holthaus, K. and Baier, M.: Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. Prostate, 38: 296, 1999
29. Ellis, W. J., Chetner, M. P., Preston, S. D. and Brawer, M. K.: Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol, 152: 1520, 1994
30. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C. et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol, 151: 1283, 1994
31. Nakamura, R. M., Abrahamsson, P. A., Chopin, D., Elgamal, A. A., Neels, H., Stenman, H. et al: Progress in standardization and quality assessment of free PSA (Prostate Specific Antigen), total PSA, and complexed PSA immunoassays. In: Proceedings of the 2nd International Consultation on Prostate Cancer. Edited by G. Murphy, S. Khoury, A. Partin and L. Denis. Paris, France: Health Publication Ltd., June 27-29, 1999
32. Semjonow, A., De Angeles, G., Oberpenning, F., Schmidt, H. P., Brandt, B. and Hertle, L.: The clinical impact of different assays for prostate specific antigen. BJU Int, 86: 590, 2000
33. Brawer, M. K.: Prostate-specific antigen. Semin Surg Oncol, 18: 3, 2000
34. Polascik, T. J., Oesterling, J. E. and Partin, A. W.: Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol, 162: 293, 1999
35. Hammerer, P. G., McNeal, J. E. and Stamey, T. A.: Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol, 153: 111, 1995
36. Nadler, R. B., Humphrey, P. A., Smith, D. S., Catalona, W. J. and Ratliff, T. L.: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol, 154: 407, 1995
37. Irani, J., Levillain, P., Goujon, J.-M., Bon, D., Doré, B. and Aubert, J.: Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol, 157: 1301, 1997
38. Brawer, M. K., Chetner, M. P., Beatie, J., Buchner, D. M., Vessella, R. L. and Lange, P. H.: Screening for prostatic carcinoma with prostate specific antigen. J Urol, part 2, 147: 841, 1992
39. Mettlin, C., Lee, F., Drago, J. and Murphy, G. P.: The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer, 67: 2949, 1991
40. Bretton, P. R.: Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a communitybased study. South Med J, 87: 720, 1994
41. Catalona, W. J., Smith, D. S., Ratliff, T. L. and Basler, J. W.: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA, 270: 948, 1993
42. Catalona, W. J., Smith, D. S. and Ornstein, D. K.: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA, 277: 1452, 1997
43. Catalona, W. J., Partin, A. W., Finlay, J. A., Chan, D. W., Rittenhouse, H. G., Wolfert, R. L. et al: Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology, 54: 220, 1999
44. Djavan, B., Zlotta, A., Kratzik, C., Remzi, M., Seitz, C., Schulman, C. C. et al: PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology, 54: 517, 1999
45. Babaian, R. J., Ayala, A., Bhadkamkar, V., Naccarato, W. and Fritsche, H.: The incidence of prostate cancer in the PSA reflex range of 2.5 and 4.0 ng/ml. J Urol, suppl., 163: 88, abstract 386, 2000
46. Stenman, U. H., Hakama, M., Knekt, P., Aromaa, A., Teppo, L. and Leinonen, J.: Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet, 344: 1594, 1994
47. Gann, P. H., Hennekens, C. H. and Stampfer, M. J.: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA, 273: 289, 1995
48. Smith, D. S., Catalona, W. J. and Herschman, J. D.: Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA, 276: 1309, 1996
49. Schroder, F. H, van der Cruijsen-Koeter, I., deKoning, H. J., Vis, A. N., Hoedemaeker, R. F. and Krause, R.: Prostate cancer detection at low prostate specific antigen. J Urol, 163: 806, 2000
50. Horninger, W., Reissigl, A., Rogatsch, H., Volgger, H., Studen, M., Klocker, H. et al: Prostate cancer screening in the Tyrol, Austria: experience and results. Eur J Cancer, 36: 1322, 2000
51. Oesterling, J. E., Cooner, W. H., Jacobsen, S. J., Guess, H. A. and Lieber, M. M.: Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am, 20: 671, 1993
52. Dalkin, B. L., Ahmann, F. R. and Kopp, J. B.: Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol, 150: 1837, 1993
53. Bangma, C. H, Krause, R., Blijenberg, B. G. and Schroder, F. H.: The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostatespecific analysis ratio, age-specific reference ranges, and PSA density. Urology, 46: 779, 1995
54. Dalkin, B. L., Ahmann, F. R., Kopp, J. B., Catalona, W. J., Ratliff, T. L., Hudson, M. A. et al: Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma. Br J Urol, 76: 346, 1995
55. DeAntoni, E. P., Crawford, E. D., Oesterling, J. E., Ross, C. A., Berger, E. R., McLeod, D. G. et al: Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology, 48: 234, 1996
56. Morgan, T. O., Jacobsen, S. J., McCarthy, W. F., Jacobson, D. J., McLeod, D. G. and Moul, J. W.: Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med, 335: 304, 1996
57. Lofman, O., Lindahl, T. and Varenhorst, E.: Age-specific reference values for serum prostate-specific antigen in a community-based population of healthy Swedish men. Scand J Clin Lab Invest, 57: 225, 1997
58. Lein, M., Koenig, F., Jung, K., McGovern, F. J., Skates, S. J., Schnorr, D. et al: The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br J Urol, 82: 231, 1998
59. Kalish, L. A. and McKinlay, J. B.: Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: age-specific reference ranges for total PSA, free PSA, and percent free PSA. Urology, 54: 1022, 1999
60. Ito, K., Yamamoto, T., Kubota, Y., Suzuki, K., Fukabori, Y., Kurokawa, K. et al: Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology, 56: 278, 2000
61. Anderson, J. R., Strickland, D., Corbin, D., Byrnes, J. A. and Zweiback, E.: Age-specific reference ranges for serum prostate-specific antigen. Urology, 46: 54, 1995
62. Lankford, S. P., Peters, K. L. and Elser, R. C.: Potential effects of age-specific reference ranges for serum prostate-specific antigen. Eur Urol, 27: 182, 1995
63. Catalona, W. J., Southwick, P. C., Slawin, K. M., Partin, A. W., Brawer, M. K., Flanigan, R. C. et al: Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology, 56: 255, 2000
64. Hofer, C., Sauerstein, P., Wolter, C., Scholz, M., Hartung, R. and Breul, J.: Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist. Urol Int, 64: 18, 2000
65. Richardson, T. D. and Oesterling, J. E.: Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am, 24: 339, 1997
66. Oesterling, J. E., Jacobsen, S. J. and Cooner, W. H.: The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol, 153: 1160, 1995
67. Partin, A. W., Criley, S. R., Subong, E. N., Zincke, H., Walsh, P. C. and Oesterling, J. E.: Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. J Urol, 155: 1336, 1996
68. Borer, J. G., Sherman, J., Solomon, M. C., Plawker, M. W. and Macchia, R. J.: Age specific prostate specific antigen reference ranges: population specific. J Urol, 159: 444, 1998
69. Carter, H. B., Pearson, J. D., Metter, E. J., Brant, L. J., Chan, D. W., Andres, R. et al: Longitudinal evaluation of prostatespecific antigen levels in men with and without prostate disease. JAMA, 267: 2215, 1992
70. Carter, H. B., Morrell, C. H., Pearson, J. D., Brant, L. J., Plato, C. C., Metter, E. J. et al: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res, 52: 3323, 1992
71. Carter, H. B., Pearson, J. D., Waclawiw, Z., Metter, E. J., Chan, D. W., Guess, H. A. et al: Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology, 45: 591, 1995
72. Carter, H. B. and Pearson, J. D.: Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am, 24: 333, 1997
73. Smith, D. S. and Catalona, W. J.: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol, 152: 1163, 1994
74. Lujan, M., Paez, A., Sanchez, E., Herraro, A., Martin, E. and Berenguer, A.: Prostate specific antigen variation in patients without clinically evident prostate cancer. J Urol, 162: 1311, 1999
75. Manseck, A., Pilarsky, C., Froschermaier, S., Menschikowski, M. and Wirth, M. P.: Diagnostic significance of prostatespecific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems. Urol Int, 60: 25, 1998
76. Borboroglu, P. G., Comer, S. W., Riffenburgh, R. H. and Amling, C. L.: Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol, 163: 158, 2000
77. Fowler, J. E., Jr., Bigler, S. A., Miles, D. and Yalkut, D. A.: Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer. J Urol, 163: 813, 2000
78. Benson, M. C., Whang, I. S., Pantuck, A., Ring, K., Kaplan, S. A., Olsson, C. A. et al: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol, part 2, 147: 815, 1992
79. Kalish, J., Cooner, W. H. and Graham, S. D., Jr.: Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology, 43: 601, 1994
80. Gohji, K., Nomi, M., Egawa, S., Morisue, K., Takenaka, A., Okamoto, M. et al: Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Cancer, 79: 1969, 1997
81. Maeda, H., Arai, Y., Ishitoya, S., Okubo, K., Aoki, Y. and Okada, T.: Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer. J Urol, 158: 2193, 1997
82. Kikuchi, E., Nakashima, J., Ishibashi, M., Ohigashi, T., Asakura, H., Tachibana, M. et al: Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma. Cancer, 89: 842, 2000
83. Lin, D. W., Gold, M. H., Ransom, S., Ellis, W. J. and Brawer, M. K.: Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma. J Urol, 160: 77, 1998
84. Zlotta, A. R., Djavan, B., Marberger, M. and Schulman, C. C.: Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol, 157: 1315, 1997
85. Morote, J., Raventos, C. X., Lorente, J. A., Lopez-Pacios, M. A., Encabo, G., de Torres, I. et al: Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. J Urol, 158: 502, 1997
86. Kuriyama, M., Uno, H., Watanabe, H., Yamanaka, H., Saito, Y. and Shida, K.: Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels. Jpn J Clin Oncol, 29: 617, 1999
87. Djavan, B., Zlotta, A. R., Byttebier, G., Shariot, S., Omar, M., Schulman, C. C. et al: Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol, 160: 411, 1998
88. Reissigl, A., Horninger, W., Fink, K., Klocker, H. and Bartsch, G.: Prostate carcinoma screening in the county of Tyrol, Austria: experience and results. Cancer, 80: 1818, 1997
89. Vleeming, R., de Craen, A. J., de Reijke, T. M., van Andel, G. and Kurth, K. H.: Does prostate-specific antigen density alter decision making on biopsy? Eur Urol, 29: 10, 1996
90. Akdas, A., Tarcan, T., Turkeri, L., Cevik, I., Biren, T. and Ilker, Y.: The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml. Eur Urol, 29: 189, 1996
91. Kuriyama, M., Kawada, Y., Arai, Y., Maeda, H., Egawa, S., Koshiba, K. et al: Significance of free to total PSA ratio in men with slightly elevated serum PSA levels: a cooperative study. Jpn J Clin Oncol, 28: 661, 1998
92. Partin, A. W., Brawer, M. K., Subong, E. N. P., Kelley, C. A., Cox, J. L., Bruzek, D. J. et al: Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis, 1: 197, 1998
93. Trinkler, F. B., Schmid, D. M., Hauri, D., Pei, P., Maly, F. E. and Sulser, T.: Free/total prostate-specific antigen ratio can prevent unnecessary prostate biopsies. Urology, 52: 479, 1998
94. Veltri, R. W. and Miller, M. C.: Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations. Urology, 53: 736, 1999
95. Basso, D., Fogar, P., Piva, M. G., Navaglia, F., Mazza, S., Prayer-Galetti, T. et al: Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? Urology, 55: 710, 2000
96. Vessella, R. L., Lange, P. H., Partin, A. W., Chan, D. W., Sokoll, L. J., Sasse, E. A. et al: Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. Urology, 55: 909, 2000
97. Fleshner, N. E., O'Sullivan, M. and Fair, W. R.: Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol, 158: 505, 1997
98. Ukimura, O., Durrani, O. and Babaian, R. J.: Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology, 50: 66, 1997
99. Djavan, B., Zlotta, A., Remzi, M., Ghawidel, K., Basharkhah, A., Schulman, C. C. et al: Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol, 163: 1144, 2000
100. Hasui, Y., Marutsuka, K., Asada, Y., Ide, H., Nishi, S. and Osada, Y.: Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate, 25: 91, 1994
101. Atan, A., Horn, T., Hansen, F., Jakobsen, H. and Hald, T.: Prostatic specific antigen and benign prostatic hyperplasia. Scand J Urol Nephrol, 30: 299, 1996
102. Morote, J., Lopez, M., Encabo, G. and de Torres, I. M.: Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur Urol, 37: 537, 2000
103. Ferrero Doria, R., Perez Flores, D., Terrer Artes, C., Guzman Martinez-Valls, P. L., Morga Egea, J. P., Tomas Ros, M. et al: Impact of prostate benign hyperplasia and prostatic inflammation on the increase of prostate specific antigen levels. Actas Urol Esp, 21: 100, 1997
104. Schatteman, P. H., Hoekx, L., Wyndaele, J. J., Jeuris, W. and Van Marck, E.: Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol, 37: 404, 2000
105. Nickel, J. C., Downey, J., Young, I. and Boag, S.: Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int, 84: 976, 1999
106. Okada, K., Kojima, M., Naya, Y., Kamoi, K., Yokoyama, K., Takamatsu, T. et al: Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology, 55: 892, 2000
107. Dalton, D. L.: Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology, 33: 465, 1989
108. Yamamoto, M., Hibi, H. and Miyake, K.: Prostate-specific antigen levels in acute and chronic bacterial prostatitis. Hinyokika Kiyo, 39: 445, 1993
109. Karazanashvili, G. and Managadze, L.: Prostate specific antigen (PSA) value change after the antibacterial therapy for prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4-10 ng/ml and nonsuspicious results of digital rectal examination. Eur Urol, 39: 538, 2001
110. Potter, S. R., Reckwitz, T. and Partin, A. W.: The use of percent free PSA for early detection of prostate cancer. J Androl, 20: 449, 1999
111. Letran, J. L., Blase, A. B., Loberiza, F. R., Meyer, G. E., Ransom, S. D. and Brawer, M. K.: Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. J Urol, 160: 426, 1998
112. Lilja, H., Cockett, A. T. and Abrahamsson, P. A.: Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum. Cancer, suppl., 70: 230, 1992
113. Okegawa, T., Noda, H., Nutahara, K. and Higashihara, E.: Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer. Eur Urol, 38: 380, 2000
114. Allard, W. J., Zhou, Z. and Yeung, K. K.: Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem, 44: 1216, 1998
115. Brawer, M. K., Cheli, C. D., Neaman, I. E., Goldblatt, J., Smith, C., Schwartz, M. K. et al: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol, 163: 1476, 2000
116. Okegawa, T., Noda, H., Nutahara, K. and Higashihara, E.: Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. Urology, 55: 700, 2000
117. Maeda, H., Arai, Y., Aoki, Y., Okubo, K., Okada, T. and Maekawa, S.: Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology, 54: 225, 1999
118. Jung, K., Brux, B., Lein, M., Knabich, A., Sinha, P., Rudolph, B. et al: Determination of alpha 1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Urology, 53: 1160, 1999
119. Martinez, M., Espana, F., Royo, M., Vera, C. D., Estelles, A., Jimenez-Cruz, J. F. et al: Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer. Eur Urol, 38: 85, 2000
120. Zhang, W. M., Finne, P., Leinonen, J., Vesalainen, S., Nordling, S. and Stenman, U. H.: Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem, 45: 814, 1999
121. Zhang, W. M., Finne, P., Leinonen, J., Vesalainen, S., Nordling, S., Rannikko, S. et al: Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem, 44: 2471, 1998
122. Zhang, W. M., Finne, P., Leinonen, J., Salo, J. and Stenman, U. H.: Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology, 56: 267, 2000
123. Lilja, H.: Prostate-specific antigen: molecular forms and the human kallikrein gene family. Br J Urol, suppl., 79: 44, 1997
124. Schedlich, L. J., Bennetts, B. and Morris, B. J.: Primary structure of a human glandular kallikrein gene. DNA, 6: 429, 1987
125. Lovgren, J., Piironen, T., Overmo, C., Dowell, B., Karp, M., Pettersson, K. et al: Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun, 213: 888, 1995
126. Piironen, T., Lovgren, J., Karp, M., Eerola, R., Lundwall, A., Dowell, B. et al: Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem, 42: 1034, 1996
127. Darson, M. F., Pacelli, A., Roche, P., Rittenhouse, H. G., Wolfert, R. L., Saeid, M. S. et al: Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology, 53: 939, 1999
128. Tremblay, R. R., Deperthes, D., Tetu, B. and Dube, J. Y.: Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol, 150: 455, 1997
129. Becker, C.: Human glandular kallikrein 2 (hK2) in prostate cancer. Clinical and methodological studies. In: Lund University Dissertation Abstracts. Malmo, Sweden: Lund University, 2000
130. Kwiatkowski, M. K., Recker, F., Piironen, T., Pettersson, K., Otto, T., Wernli, M. et al: In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology, 52: 360, 1998
131. Recker, F., Kwiatkowski, M. K., Piironen, T., Pettersson, K., Lummen, G., Wernli, M. et al: The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer, 83: 2540, 1998
132. Partin, A. W., Catalona, W. J., Finlay, J. A., Darte, C., Tindall, D. J., Young, C. Y. et al: Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology, 54: 839, 1999
133. Becker, C., Piironen, T., Pettersson, K., Hugosson, J. and Lilja, H.: Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology, 55: 694, 2000
134. Espana, F., Royo, M., Martinez, M., Enguidanos, M. J., Vera, C. D., Estelles, A. et al: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. J Urol, 160: 2081, 1998
135. Djavan, B., Remzi, M., Zlotta, A. R., Seitz, C., Wolfram, R., Hruby S. et al: Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction. Tech Urol, 5: 71, 1999